Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (cGMP) quality control. Our team has extensive clinical development experience and is laser-focused on advancing novel gene therapies for patients. Source
No articles found.
ImmuCell Corporationâs (Nasdaq: ICCC) purpose is to create scientifically-proven...
ImmuCell Corporationâs (Nasdaq: ICCC) purpose...
HealthEquity provides a solution to an issue of growing importance to American fam...
HealthEquity provides a solution to an issue of...
Dova is a pharmaceutical company focused on acquiring, developing and commercializ...
Dova is a pharmaceutical company focused on acq...
GenMark Diagnostics (NASDAQ: GNMK) is a leading provider of multiplex molecular di...
GenMark Diagnostics (NASDAQ: GNMK) is a leading...
Avalon GloboCare Corp. (NASDAQ: AVCO) is a global intelligent biotech developer an...
Avalon GloboCare Corp. (NASDAQ: AVCO) is a glob...
Aviana Molecular Technologies, LLC (Aviana) is an Orlando, FL based point of care ...
Aviana Molecular Technologies, LLC (Aviana) is ...
Orchard Therapeutics is a fully integrated commercial-stage biopharmaceutical comp...
Orchard Therapeutics is a fully integrated comm...
Join the National Investor Network and get the latest information with your interests in mind.